Related Experiment Videos

An amebic anti-inflammatory peptide down-regulates ex vivo IL-1β expression in patients with rheumatoid arthritis

Juan R Velázquez1, Lizeth Garibay-Martínez, Pedro Martínez-Tejada

  • 1Departamento de Inmunogénetica y Alergia, INER, México, D.F., Mexico. velazquez_juan@hotmail.com

Reumatologia Clinica
|July 4, 2012
PubMed
Abstract

Insights

The Entamoeba histolytica-derived monocyte locomotion inhibitory factor (MLIF) shows anti-inflammatory effects by down-regulating interleukin-1β (IL-1β) in specific immune cells. This peptide

Area of Science:

  • Immunology
  • Parasitology
  • Molecular Biology

Background:

  • Monocyte Locomotion Inhibitory Factor (MLIF) is a pentapeptide from Entamoeba histolytica.
  • MLIF exhibits anti-inflammatory properties, including inhibition of monocyte functions and inflammatory gene expression.
  • Previous studies show MLIF's efficacy in animal models of inflammation.

Purpose of the Study:

  • To investigate the in vitro anti-inflammatory capacity of MLIF.
  • To assess MLIF's effect on interleukin-1β (IL-1β) expression in human cell lines and primary cells.
  • To compare MLIF's activity in cells from healthy individuals and rheumatoid arthritis (RA) patients.

Main Methods:

  • Human promonocytic U-937 cells and peripheral blood mononuclear cells (PBMC) were used.
  • Cells were treated with MLIF, lipopolysaccharide (LPS), or both.
  • IL-1β gene expression and protein levels were measured.

Main Results:

  • MLIF down-regulated LPS-induced IL-1β expression in U-937 cells.
  • MLIF reduced both baseline and LPS-induced IL-1β expression in PBMC from RA patients.
  • MLIF did not significantly affect IL-1β protein levels or bioavailability.

Conclusions:

  • MLIF demonstrates potent anti-inflammatory effects on primed immune cells.
  • The peptide's mechanism of action warrants further investigation.
  • MLIF shows potential therapeutic relevance for inflammatory conditions like RA.

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Inflammatory Response01:28

Inflammatory Response

An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...